论文部分内容阅读
多不饱和脂肪酸(PUFA)富含二十碳五烯酸(EPA)和γ-亚麻酸(GLA),治疗急性肺损伤(ALI)/急性呼吸窘迫综合征(ARDS)是近年来的又一进展。迄今为止,EPA+GLA的肠内营养(EN)制剂用于ALI/ARDS治疗的前瞻性、随机、双盲对照试验已有四项。其结论显示,EPA+GLA的EN治疗ALI/ARDS,有助于早期改善病人的氧合情况和缩短机械通气时间,同时改善呼吸力学情况、缩短ICU入住时间、减少新发器官功能衰竭以及改善生存等。EPA+GLA的EN治疗ALI/ARDS的临床随机对照试验结果仍存在异质性和局限性,需要进一步大型随机对照临床试验。
Polyunsaturated fatty acids (PUFA) are rich in eicosapentaenoic acid (EPA) and gamma-linolenic acid (GLA) and are a further advance in recent years in the treatment of acute lung injury (ALI) / acute respiratory distress syndrome . To date, there are four prospective, randomized, double-blind, controlled trials of enteral nutrition (EN) formulations of EPA + GLA for ALI / ARDS. The results show that EPA + GLA EN treatment of ALI / ARDS can help to improve the patient’s oxygenation and shorten the duration of mechanical ventilation at the same time. At the same time, it can improve the respiratory mechanics, shorten the ICU admission time, reduce new organ failure and improve survival Wait. The clinical and randomized controlled trials of EPA + GLA EN in the treatment of ALI / ARDS are still heterogeneous and limited and require further large randomized controlled clinical trials.